Indaptus Therapeutics Inc (INDP)
Featured in
Bullish Trend Stocks
Low-Float Small-Cap Momentum Stocks
High-Growth Small-Cap Stocks
Under $10 per Share
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company listed on NASDAQ under the ticker INDP. The company focuses on developing immunotherapy candidates for cancer and viral diseases. Its lead clinical program is Decoy20, a product being studied for potential single-agent and combination use in a range of indications, including lymphoma, hepatocellular, colorectal and pancreatic tumors, advanced solid tumors, chronic hepatitis B, and HIV infection. The company was previously known as Intec Parent, Inc. and adopted its current name in August 2021. Indaptus Therapeutics is headquartered in New York, New York.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-INDP
|
$2.05
|
-48.5% Downside
|
Overvalued
|
$10
|
150.6% Upside
|
Bargain
|
Fair
|
0.0%
|
November 13, 2026
|
36.2x
|
531.6 M
|
400.2 M
|
0.0%
|
17.5%
|
402.8
|
95.3%
|
